International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationsOverexpression of p53 Protein Does Not Predict Local-Regional Control or Survival in Patients With Early-Stage Squamous Cell Carcinoma of the Glottic Larynx Treated With Radiotherapy
Introduction
Squ amous cell carcinoma (SCC) of the larynx, when diagnosed at an early stage, is a highly curable disease. Radiation therapy is indicated for early-stage invasive glottic carcinoma in most cases. Excellent local-regional control and cause-specific survival rates are observed with radiation therapy [1]. There is, however, a subset of patients who fail radiation treatment. Although a good percentage of these cases can be surgically salvaged, the added morbidity and cost of a laryngectomy procedure following a full course of radiation therapy adversely impacts on patient quality of life. Treatment factors that affect outcome include radiation fraction size, total dose, technique, and overall treatment time 2, 3, 4, 5, 6. Stage and bulk of disease are well-known tumor-related factors predictive of outcome. The intent of this study was to search for other tumor-related factors that may identify patients at risk for failure to radiation therapy. We, therefore, embarked upon studying the prognostic significance of abnormal p53 tumor-suppressor gene expression in early-stage glottic SCC.
The p53 gene has been extensively studied and represents the most common mutated gene in human malignancies, including SCC of the head and neck mucosal sites. Normally functioning wild-type p53 protein (w-p53) possesses cell regulatory functions, including apoptosis, which has been shown to be an important pathway for tumor cell death following exposure to therapeutic radiation 7, 8. The protein product derived from mutated p53 (m-p53) gene is nonfunctional and blocks cells from undergoing apoptosis following irradiation. These cells continue to proliferate, despite injury due to ionizing radiation. Consequently, tumor cells that possess m-p53 are believed to be more radioresistant than those with w-p53. Aberrant p53 can be detected by several methods, including DNA sequencing and immunohistochemical staining with specific commercially prepared antihuman p53 monoclonal antibodies. The latter represents a relatively inexpensive and rapid technique. Malignant cells possessing abnormal p53 protein will stain positive owing to the fact that m-p53 protein has a longer half-life than w-p53 and, thus, stains more readily.
The purpose of this study was to determine whether or not the expression of aberrant p53 was predictive of local-regional control and survival for early-stage glottic SCC treated with radiation therapy. In comparison to previous studies investigating the significance of p53 overexpression, possible confounding factors were controlled for by selecting patients with similarly staged head and neck cancer from one specific site who were treated in a uniform fashion with radiotherapy in this study.
Section snippets
Patients
The medical records of 86 patients with early-stage (TMN Stage T1N0M0, T2N0M0) SCC of the glottic larynx who were treated with radiation therapy alone at the Sir Mortimer B. Davis - Jewish General Hospital between December 1978 and June 1995 were retrospectively reviewed. Patients were grouped according to stage (I vs. II). Patient and tumor characteristics are listed in Table 1.
Immunohistochemistry
Archival tissue samples retrieved from paraffin blocks processed at the time of diagnosis were cut, mounted on
Results
Cell nuclei staining positive for p53 (indicating presence of abnormal p53 protein) was noted in 60% (52 of 86) of patients. As shown in Table 1 p53 expression (negative vs. positive) was not predictive of T-stage (T1 vs. T2) or smoking status by Fisher’s exact test with p values of 0.81 and 0.47, respectively. Chi-squared test for independence revealed that m-p53 status (negative vs. positive) did not predict histological grade (p = 0.65).
Dose was found to be a significant factor affecting
Discussion
The presence of nonfunctional p53 is unquestionably a marker of abnormal cell population. The presence of mutated p53 (m-p53) has also been shown to be of prognostic significance in certain human tumor lines, such as transitional cell carcinoma of the bladder, locally advanced adenocarcinoma of the colon, and prostate adenocarcinoma 12, 13, 14. Whether or not the presence of m-p53 is a prognostic factor in head and neck SCC remains undefined. Studies supporting this hypothesis include those of
Acknowledgements
We are extremely grateful to Martine Bourdeau for her technical assistance.
References (27)
- et al.
Do overall treatment time, field size, and treatment energy influence local control of T1-T2 squamous cell carcinoma of the glottic larynx
Int. J. Radiat. Oncol. Biol. Phys.
(1996) - et al.
Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis
Int. J. Radiat. Oncol. Biol. Phys.
(1993) - et al.
The effect of fraction size on control of early-stage glottic cancer
Int. J. Radiat. Oncol. Biol. Phys.
(1988) - et al.
Does prolonged treatment course adversely affect local control or carcinoma of the larynx?
Int. J. Radiat. Oncol. Biol. Phys.
(1994) - et al.
The impact of radiation therapy fraction size on local control of early glottic carcinoma
Int. J. Radiat. Oncol. Biol. Phys.
(1997) - et al.
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
Cell
(1994) - et al.
P53 overexpression in head and neck carcinoma and radiotherapy results
Int. J. Radiat. Oncol. Biol. Phys.
(1996) - et al.
Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer
Otolaryngol. Head Neck Surg.
(1995) - et al.
Tumors of the larynx and hypopharynx
- et al.
Thymocyte apoptosis induced by p53-dependent and independent pathways
Nature
(1993)
P53 is required for radiation-induced apoptosis in mouse thymocytes
Nature
Nonparametric estimations from incomplete observations
J. Am. Stat. Assoc.
Evaluation of survival data and two new rank order statistics arising in its considerations
Cancer Chemother. Rep.
Cited by (45)
Early glottic cancer recurrence: A critical review on its current management
2021, Critical Reviews in Oncology/HematologyCitation Excerpt :Schrijvers et al., 2008) Years later and in the same cohort, the authors also showed that high levels of a key regulator of the cell cycle, Fas-associated death domain (FADD), were associated with better local control rate (HR, 2.40; 95 % CI, 1.04–5.55) (Schrijvers et al., 2012). Instead, a group from McGill University found that mutated p53 protein detected by IHC was not a significant prognostic factor for EGC treated by RT (Pai et al., 1998). Other IHC markers that have been recently used include the metastasis-associated in colon cancer 1 (MACC1) which is a significant predictor of local recurrence for EGC (Makino et al., 2020), whereas the prominin-1/CD133, a cancer stem cell biomarker, did not correlate with prognosis of rEGC (Gülmez et al., 2020).
Non-Small Cell Lung Cancer
2015, Clinical Radiation OncologyNon-Small Cell Lung Cancer
2012, Clinical Radiation Oncology: Third EditionNon–Small Cell Lung Cancer
2011, Clinical Radiation Oncology, Third EditionCancer of the Larynx
2010, Leibel and Phillips Textbook of Radiation Oncology, Third EditionPrognostic significance of G<inf>1</inf> cell-cycle inhibitors in early laryngeal cancer
2005, American Journal of Otolaryngology - Head and Neck Medicine and Surgery